Skip to Main Content

Yale SPORE in Lung Cancer News

  • Dr Goldberg on Investigational Agents in EGFR-mutant NSCLC

    Sarah Goldberg, MD, MPH, associate professor, internal medicine (medical oncology), associate director, Medical Oncology-Hematology Program, research director, Center for Thoracic Cancers, chief, Thoracic Oncology, Yale School of Medicine, discusses ongoing investigations with antibody-drug conjugates (ADCs) and bispecific antibodies in patients with non–small cell lung cancer (NSCLC) harboring EGFR mutations.

    Source: OncLive
    Read more
  • Yale Cancer Center and Smilow Cancer Hospital Physicians and Scientists Presenting Latest Advances at 2023 ASCO Annual Meeting

    Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians will present new research at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 2nd to June 6th at McCormick Place in Chicago, Illinois. This year’s scientific program will feature more than 2,900 abstracts, covering all major diseases and research areas, including breast, lung, head and neck, gynecological, prostate, and gastric cancers.

    Read more
  • AEGEAN Trial Shows Benefit With Immunotherapy-Based Combination for NSCLC

    Patients with treatment-naive resectable non–small cell lung cancer (NSCLC) treated with neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival and pathologic complete response rates compared with those who received neoadjuvant chemotherapy alone, according to an interim analysis of event-free survival and a final analysis of pathologic complete response in the phase III AEGEAN trial reported at the American Association for Cancer Research (AACR) 2023 Annual Meeting.

    Source: ASCO Post
    Read more
  • Dr. Herbst on the Implications of the AEGEAN Trial in NSCLC

    Roy S. Herbst, MD, PhD, discusses the implications of the phase 3 AEGEAN trial (NCT03800134) in patients with resectable non–small cell lung cancer (NSCLC). At the 2023 AACR Annual Meeting, preliminary findings from the phase 3 trial were read out from the first interim analysis. The AEGEAN trial evaluated patients that received perioperative durvalumab (Imfinzi) plus neoadjuvant platinum-based chemotherapy compared with placebo with chemotherapy, Herbst begins, noting that the trial was positive. Investigators reported a hazard ratio of 0.68 and a 32% improvement in event-free survival (EFS). Moreover, the pathologic complete response rate was 17.2% compared with 4.3% in the control arm. However, the median follow-up was only 11.7 months, so the data are still early, Herbst expands.

    Source: OncLive
    Read more
  • Durvalumab Pre, Post Surgery in NSCLC: Practice Changing?

    After excluding patients with targetable EGFR/ALK alterations, the team randomly allocated 740 patients who had good performance status (ECOG 0 or 1) to receive either neoadjuvant chemoimmunotherapy plus adjuvant immunotherapy or neoadjuvant chemotherapy alone.

    Source: Medscape
    Read more
  • Dr. Roy Herbst Shares Practice-Changing Highlights From the 2023 AACR Annual Meeting

    From cancer vaccine efficacy to developments in lung cancer, Roy S. Herbst, MD, PhD, professor of medicine, medical oncology, chief of medical oncology at Yale Cancer Center, discusses key clinical highlights from practice-changing research presented during the 2023 American Association for Cancer Research (AACR) Annual Meeting. Dr. Herbst, who chairs AACR’s Scientific Policy and Government Affairs Committee, also discusses the organization’s policy efforts and shares what has him excited about this year’s gathering.

    Source: Oncology Business Review
    Read more